Chapter 8 - Passive/Adoptive Immunotherapy

Barbara Barnes Rogers

Chapter 8 details passive/adoptive immunotherapy, including information on tumor-targeting monoclonal antibodies and epidermal growth factor receptor–specific monoclonal antibodies, as well as common side effects associated with both passive and adoptive immunotherapies.

Agents detailed include Cetuximab, Panitumumab, Trastuzumab, Pertuzumab, Bevacizumab, Ramucirumab, Rituximab, Ofatumumab, Obinutuzumab, Brentuximab Vedotin, Ado-Trastuzumab Emtansine, Gemtuzumab Ozogamicin, and Inotuzumab Ozogamicin. 

Price: $12.95